Arch Therapeutics, Inc.
(Other OTC/NBB : ARTH)

( )
ARTH PreMarket: $ () as of AM
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield

Message Boards



Health Technology » Biotechnology

Company Profile

Arch Therapeutics, Inc. is a biotechnology company, which engages in developing an innovative, elegant, and superior approach to the rapid cessation of bleeding and control of fluid leakage during surgery and trauma care. Its product candidate surgical hemostatic device is designed to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.